Hiroshi Imazeki

473 total citations
31 papers, 308 citations indexed

About

Hiroshi Imazeki is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Hiroshi Imazeki has authored 31 papers receiving a total of 308 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Surgery, 19 papers in Pulmonary and Respiratory Medicine and 18 papers in Oncology. Recurrent topics in Hiroshi Imazeki's work include Gastric Cancer Management and Outcomes (15 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Esophageal Cancer Research and Treatment (13 papers). Hiroshi Imazeki is often cited by papers focused on Gastric Cancer Management and Outcomes (15 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Esophageal Cancer Research and Treatment (13 papers). Hiroshi Imazeki collaborates with scholars based in Japan, United States and United Kingdom. Hiroshi Imazeki's co-authors include Narikazu Boku, Ken Kato, Hirokazu Shoji, Takahiro Miyamoto, Yoshitaka Honma, Satoru Iwasa, Hidekazu Hirano, Kengo Nagashima, Atsuo Takashima and Natsuko Okita and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Hiroshi Imazeki

22 papers receiving 307 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hiroshi Imazeki Japan 10 206 143 74 72 54 31 308
C. Zingaretti Italy 3 187 0.9× 139 1.0× 91 1.2× 131 1.8× 59 1.1× 6 351
Hiroyuki Hanayama Japan 10 155 0.8× 104 0.7× 101 1.4× 85 1.2× 81 1.5× 40 297
Ekaterina Petrova Germany 12 264 1.3× 146 1.0× 190 2.6× 28 0.4× 39 0.7× 42 353
Zhixue Zheng China 10 185 0.9× 170 1.2× 96 1.3× 77 1.1× 70 1.3× 19 353
S-A Im South Korea 5 246 1.2× 158 1.1× 42 0.6× 73 1.0× 75 1.4× 19 326
Seung Tae Kim South Korea 9 186 0.9× 169 1.2× 89 1.2× 53 0.7× 67 1.2× 16 322
Mahmood Al‐Dhaheri Qatar 8 202 1.0× 73 0.5× 72 1.0× 149 2.1× 53 1.0× 19 321
Markus Moehler Germany 9 207 1.0× 175 1.2× 126 1.7× 45 0.6× 55 1.0× 24 320
Zhongmin Maxwell Wang Australia 10 210 1.0× 70 0.5× 31 0.4× 117 1.6× 49 0.9× 17 330
Norimichi Kan Japan 11 136 0.7× 143 1.0× 113 1.5× 84 1.2× 35 0.6× 36 347

Countries citing papers authored by Hiroshi Imazeki

Since Specialization
Citations

This map shows the geographic impact of Hiroshi Imazeki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Imazeki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Imazeki more than expected).

Fields of papers citing papers by Hiroshi Imazeki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshi Imazeki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Imazeki. The network helps show where Hiroshi Imazeki may publish in the future.

Co-authorship network of co-authors of Hiroshi Imazeki

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroshi Imazeki. A scholar is included among the top collaborators of Hiroshi Imazeki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroshi Imazeki. Hiroshi Imazeki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shoji, Hirokazu, Natsuko Okita, Hiroyuki Takamaru, et al.. (2025). A safety trial of antibiotic fecal microbiota transplantation for esophageal and gastric cancer patients treated with immune checkpoint inhibitors (Biorich2 trial).. Journal of Clinical Oncology. 43(4_suppl). 2 indexed citations
2.
Imazeki, Hiroshi, Yoshitaka Honma, Tairo Kashihara, et al.. (2025). The safety and short-term efficacy of nivolumab plus ipilimumab for advanced esophageal squamous cell carcinoma. Esophagus. 23(1). 181–188.
3.
Imazeki, Hiroshi, Kazuo Koyanagi, Takashi Ogata, et al.. (2025). Non-cancer-related deaths in patients with resectable locally advanced esophageal squamous cell carcinoma: A supplementary analysis of JCOG1109.. Journal of Clinical Oncology. 43(4_suppl). 434–434.
4.
Sano, M., Hiroshi Imazeki, Yoshitaka Honma, et al.. (2025). The safety and short-term efficacy of induction DCF plus nivolumab therapy in patients with unresectable locally advanced esophageal squamous cell carcinoma.. Journal of Clinical Oncology. 43(4_suppl). 425–425.
5.
Kudo‐Saito, Chie, Hiroshi Imazeki, Hiroki Ozawa, et al.. (2024). Targeting SNCA in the treatment of malignant ascites in gastrointestinal cancer. Translational Oncology. 48. 102075–102075.
6.
7.
Shoji, Hirokazu, Chie Kudo‐Saito, Kengo Nagashima, et al.. (2024). Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study). Journal for ImmunoTherapy of Cancer. 12(11). e010174–e010174. 2 indexed citations
8.
Yamamoto, Satoshi, Hiroshi Imazeki, Kenichi Yokoyama, et al.. (2024). 415P Safety and short-term efficacy of neoadjuvant FLOT therapy in patients with resectable locally advanced esophageal squamous cell carcinoma. Annals of Oncology. 35. S168–S168.
9.
Oguma, Junya, Koshiro Ishiyama, Daisuke Kurita, et al.. (2024). Long-term Survival in Esophageal Cancer: Comparison of Minimally Invasive and Open Esophagectomy. The Annals of Thoracic Surgery. 119(4). 805–814. 1 indexed citations
10.
Tsushima, Takahiro, Yasuhiro Tsubosa, Akifumi Notsu, et al.. (2024). First-line FOLFOX therapy for advanced esophageal squamous cell carcinoma: Multicenter prospective study in Japan.. Journal of Clinical Oncology. 42(3_suppl). 280–280. 1 indexed citations
11.
Boku, Narikazu, Chie Kudo‐Saito, Hirokazu Shoji, et al.. (2023). LAG3-related factors to predict response to nivolumab monotherapy in advanced gastric cancer (WJOG10417GTR study).. Journal of Clinical Oncology. 41(4_suppl). 425–425. 2 indexed citations
12.
Kita, Ryosuke, Yoshitomo Yanagimoto, Hiroshi Imazeki, et al.. (2023). Protocol digest of a randomized controlled adaptive Phase II/III trial of neoadjuvant chemotherapy for Japanese patients with oesophagogastric junction adenocarcinoma: Japan Clinical Oncology Group Study JCOG2203 (NEO-JPEG). Japanese Journal of Clinical Oncology. 54(2). 206–211. 5 indexed citations
13.
Boku, Narikazu, Naoki Takahashi, Takeshi Kawakami, et al.. (2022). 1217P Profiling of myeloid cells associated with prognosis in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study). Annals of Oncology. 33. S1105–S1105. 1 indexed citations
14.
Ozawa, Hiroki, Hiroshi Imazeki, Hirofumi Kawakubo, et al.. (2021). Targeting AURKA in treatment of peritoneal tumor dissemination in gastrointestinal cancer. Translational Oncology. 16. 101307–101307. 6 indexed citations
15.
Kudo‐Saito, Chie, Hiroshi Imazeki, Narikazu Boku, et al.. (2021). CD11b+DIP2A+LAG3+ cells facilitate immune dysfunction in colorectal cancer.. PubMed. 11(11). 5428–5439. 10 indexed citations
16.
Kudo‐Saito, Chie, Takahiro Miyamoto, Hiroshi Imazeki, et al.. (2020). IL33 Is a Key Driver of Treatment Resistance of Cancer. Cancer Research. 80(10). 1981–1990. 30 indexed citations
17.
Ishikawa, Masashi, Satoru Iwasa, Kengo Nagashima, et al.. (2019). Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis. Investigational New Drugs. 38(2). 533–540. 14 indexed citations
18.
Masuda, Ken, Hirokazu Shoji, Kengo Nagashima, et al.. (2019). Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer. 19(1). 974–974. 119 indexed citations
19.
Shoji, Hirokazu, Kengo Nagashima, Hiroshi Imazeki, et al.. (2019). Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer. ESMO Open. 4(3). e000488–e000488. 37 indexed citations
20.
Masuda, Ken, Hirokazu Shoji, Kengo Nagashima, et al.. (2019). Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.. Journal of Clinical Oncology. 37(15_suppl). 4049–4049. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. Zingaretti Breakdown of academic impact, for papers by Hiroyuki Hanayama Breakdown of academic impact, for papers by Ekaterina Petrova Breakdown of academic impact, for papers by Zhixue Zheng Breakdown of academic impact, for papers by S-A Im Breakdown of academic impact, for papers by Seung Tae Kim Breakdown of academic impact, for papers by Mahmood Al‐Dhaheri Breakdown of academic impact, for papers by Markus Moehler Breakdown of academic impact, for papers by Zhongmin Maxwell Wang Breakdown of academic impact, for papers by Norimichi Kan
Rankless by CCL
2026